UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549~~STATES

~~FORM~~SECURITIES ~~8-K~~AND EXCHANGE COMMISSION

~~CURRENT~~Washington, ~~REPORT~~D.C. 20549

~~Pursuant~~FORM ~~to Section 13 or 15(d) of the Securities Exchange Act of 1934~~8-K

~~Date~~CURRENT ~~of Report (Date of earliest event reported): May 08, 2026~~REPORT

~~Alamar~~Pursuant ~~Biosciences,~~to ~~Inc.~~Section 13 or 15(d)

~~(Exact name~~ of ~~Registrant~~the asSecurities ~~Specified~~Exchange inAct ~~Its~~of ~~Charter)~~1934

Delaware	001-43235	36-4899036
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
47071 Bayside Parkway
Fremont, California		94538
(Address of Principal Executive Offices)		(Zip Code)

Date of Report (Date of earliest event reported): July 15, 2026

~~Registrant’s~~Alamar ~~Telephone Number~~Biosciences, ~~Including Area Code: (510) 626-9888~~Inc.

~~N/A~~(Exact name of registrant as specified in its charter)

(Former Name or Former Address, if Changed Since Last Report)

Delaware

001-43235

36-4899036

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

~~Check~~47071 ~~the~~Bayside ~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:~~ Parkway

~~☐Written~~Fremont, ~~communications~~CA ~~pursuant to Rule 425 under the Securities Act (17 CFR 230.425)~~94538

~~☐Soliciting~~(Address ~~material~~of ~~pursuant~~principal toexecutive ~~Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12~~offices)

~~☐Pre-commencement~~Registrant’s ~~communications~~telephone ~~pursuant~~number, toincluding ~~Rule~~area ~~14d-2~~code: (b510) ~~under the Exchange Act (17 CFR 240.14d~~626-~~2(b))~~9888

~~☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~N/A

~~Securities~~(Former ~~registered~~name ~~pursuant~~or toformer ~~Section~~address, ~~12(b)~~if ofchanged ~~the~~since ~~Act:~~last report.)

Title of each class		TradingSymbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		ALMR		The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

~~Indicate~~☐ byWritten ~~check~~communications ~~mark~~pursuant ~~whether~~to ~~the registrant is an emerging growth company as defined in~~ Rule ~~405~~425 ofunder the Securities Act of(17 ~~1933~~CFR (§ 230.~~405 of this chapter~~425) ~~or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).~~

~~Emerging~~☐ ~~growth~~Soliciting ~~company~~material ☒pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

If☐ anPre-commencement ~~emerging~~communications ~~growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided~~ pursuant to ~~Section~~Rule 1314d-2(ab) ofunder the Exchange Act. ☐(17 CFR 240.14d-2(b))

~~Item~~☐ ~~2.02~~Pre-commencement ~~Results~~communications ofpursuant ~~Operations~~to ~~and~~Rule ~~Financial~~13e-4(c) ~~Condition~~under the Exchange Act (17 CFR 240.13e-4(c))

OnSecurities ~~May~~registered 8,pursuant ~~2026,~~to ~~Alamar Biosciences, Inc.~~ Section 12(~~the “Company”~~b) ~~issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy~~ of the ~~press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.~~Act:

All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

ALMR

The Nasdaq Stock Market LLC

~~Item~~Indicate 9by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.01405 ~~Financial~~of ~~Statements~~this ~~and~~chapter) ~~Exhibits~~or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Exhibitnumber		Description
99.1		Press Release dated May 8, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Emerging growth company ☒

~~SIGNATURES~~If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Pursuant~~Item to8.01 ~~the~~Other ~~requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Events.

	Alamar Biosciences, Inc.
Date: May 8, 2026	By:	/s/ Justin McAnear
		Justin McAnear
		Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer)

Alamar Biosciences, Inc. (the “Company”) is deeply saddened to report that Ian Ratcliffe, a member of the Company’s board of directors (the “Board”), passed away on July 5, 2026. The Company’s management and Board extend their sincerest condolences to Mr. Ratcliffe’s family. Mr. Ratcliffe served as an independent director on the Board since February 2024. The Company is extremely grateful for Mr. Ratcliffe’s dedication and service to the Company.

Following Mr. Ratcliffe’s passing, the Board decreased the number of authorized directors constituting the full Board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Alamar Biosciences, Inc.

By:		/s/ Justin McAnear
		Justin McAnear
		Chief Financial Officer

Dated: July 15, 2026

Filing Compare · Alamar Biosciences, Inc.